Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of “Hold” from Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have received a consensus rating of “Hold” from the five ratings firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $8.06.

A number of research analysts have issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Friday, July 17th. Morgan Stanley set a $5.30 price target on Recursion Pharmaceuticals in a report on Monday, August 17th. Finally, Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 29th.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CEO Najat Khan sold 22,408 shares of the firm’s stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the sale, the chief executive officer owned 2,072,890 shares of the company’s stock, valued at $7,296,572.80. This trade represents a 1.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $3.34, for a total value of $100,200.00. Following the transaction, the director owned 6,158,287 shares in the company, valued at $20,568,678.58. This represents a 0.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 122,408 shares of company stock worth $434,976. Company insiders own 6.65% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in RXRX. MCF Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the second quarter worth approximately $27,000. Sequoia Financial Advisors LLC bought a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at $41,000. Fund Advisors of America Inc FL acquired a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $45,000. Integral Investment Advisors Inc. acquired a new position in shares of Recursion Pharmaceuticals in the 1st quarter valued at $39,000. Finally, MQS Management LLC bought a new position in shares of Recursion Pharmaceuticals in the 1st quarter worth $41,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Up 0.7%

NASDAQ:RXRX traded up $0.03 on Friday, hitting $3.56. 2,692,494 shares of the stock were exchanged, compared to its average volume of 17,855,953. The stock has a fifty day moving average of $3.25 and a 200-day moving average of $3.32. The stock has a market cap of $1.91 billion, a PE ratio of -3.43 and a beta of 1.07. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals has a fifty-two week low of $2.77 and a fifty-two week high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The business had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 945.94% and a negative return on equity of 50.41%. During the same period in the prior year, the company posted ($0.41) EPS. As a group, equities analysts expect that Recursion Pharmaceuticals will post -0.92 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biotechnology company that uses artificial intelligence, automation, and large-scale biological experimentation to accelerate the discovery and development of medicines. Its technology platform, known as the Recursion Operating System, integrates data from biology, chemistry, imaging, and machine learning to identify potential drug candidates and better understand disease biology.

The company develops therapies for areas including oncology, rare diseases, and neurological disorders.